1-5 of 5
Wanda Lopez, RN
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Zeev E. Estrov, MD, Gautam M. Borthakur, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Naveen Pemmaraju, MD, Koji Sasaki, MD, Naveen Garg, MD, Xuemei Wang, MS, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Wanda Lopez, RN, Ana Ayala, RN, William Plunkett, PhD, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 357.
https://doi.org/10.1182/blood-2019-131939
Published: 2019
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Nitin Jain, MD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Zeev E. Estrov, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD, Naveen Garg, MD, Xuemei Wang, MS, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wanda Lopez, RN, Ana Ayala, RN, William Plunkett, PhD, Varsha Gandhi, PhD, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 695.
https://doi.org/10.1182/blood-2018-185
Published: 2018
Journal Articles

A Phase II Trial of Nivolumab Combined with Ibrutinib for Patients with Richter Transformation

Nitin Jain, MD, Alessandra Ferrajoli, MD, Sreyashi Basu, PhD, Philip A. Thompson, MBBS, Jan A. Burger, MD PhD, Tapan M. Kadia, MD, Zeev E. Estrov, MD, Naveen Pemmaraju, MD, Wanda Lopez, RN, Beenu Thakral, MD, Joseph David Khoury, MD, Carlos E. Bueso-Ramos, MD PhD, Jorge Blando, DVM, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, James P Allison, PhD, Michael J Keating, MBBS, Padmanee Sharma, MD PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 296.
https://doi.org/10.1182/blood-2018-99-120355
Published: 2018
Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations

Nitin Jain, MD, Philip A Thompson, MBBS, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Prithviraj Bose, MD, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Naveen Garg, MD, Xuemei Wang, Varsha Gandhi, PhD, William Plunkett, PhD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wanda Lopez, RN, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Michael J Keating, William G Wierda, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 495.
https://doi.org/10.1182/blood.V130.Suppl_1.495.495
Published: 2017
Journal Articles

Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial

Nitin Jain, MD, Sreyashi Basu, PhD, Philip A Thompson, MBBS, Maro Ohanian, DO, Alessandra Ferrajoli, MD, Naveen Pemmaraju, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, Jan A Burger, MD PhD, Sattva S. Neelapu, MD, Wanda Lopez, RN, Beenu Thakral, MD, Carlos E. Bueso-Ramos, MD PhD, Jorge Blando, DVM, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, James Allison, PhD, Michael Keating, MBBS, Padmanee Sharma, MD PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2016) 128 (22): 59.
https://doi.org/10.1182/blood.V128.22.59.59
Published: 2016